Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks

American Journal of Hematology

Volumn 93, Issue 3, 2018, Pages 321-325

  Hebbel, Robert P ^a   Hedlund, Bo E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; 5 HYDROXYMETHYLFURFURAL; HEMOGLOBIN S; TETRAMER; TUCARESOL; VELARESOL; VOXELOTOR; BENZALDEHYDE DERIVATIVE; HEMATOLOGIC AGENT; OXYGEN; OXYHEMOGLOBIN; OXYHEMOGLOBIN S; PROTEIN BINDING; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANEMIA; CEREBROVASCULAR DISEASE; DRUG MECHANISM; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN SC DISEASE; HEMOLYSIS; HUMAN; HYPOXEMIA; NOTE; OXYGEN AFFINITY; OXYGEN DISSOCIATION CURVE; POLYMERIZATION; PRIORITY JOURNAL; RISK FACTOR; SICKLE CELL ANEMIA; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; BLOOD; BRAIN CIRCULATION; CHEMICALLY INDUCED; CHEMISTRY; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECT; ERYTHROCYTE DISORDER; HEMATOCRIT; HYPOXIA; METABOLISM; MICROCIRCULATION; RISK ASSESSMENT;

2,3-DIPHOSPHOGLYCERATE; ANEMIA, SICKLE CELL; BENZALDEHYDES; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; ERYTHROCYTES, ABNORMAL; HEMATOCRIT; HEMATOLOGIC AGENTS; HEMOGLOBIN, SICKLE; HEMOLYSIS; HUMANS; HYPOXIA; MICROCIRCULATION; MODELS, BIOLOGICAL; ORGAN SPECIFICITY; OXYGEN; OXYHEMOGLOBINS; POLYMERIZATION; PROTEIN BINDING; PYRAZINES; PYRAZOLES; RISK ASSESSMENT;

EID: 85041427730     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24975     Document Type: Note

References (28)

1. Oksenberg D, Dufu K, Patel MP, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016;175(1):141–153.
2. Metcalf B, Chuang C, Dufu K, et al. Discovery of GBT440, an orally bioavailable R-state stabilizer of sickle cell hemoglobin. ACS Med Chem Lett. 2017;8(3):321–326. https://doi.org/10.1021/acsmedchemlett.6b00491
3. Dufu K, Lehrer-Graiwer J, Ramos E, Oksenberg D. GBT440 inhibits sickling of sickle cell trait blood under in vitro conditions mimicking strenuous exercise. Hematol Rep. 2016;8(3):6637.
4. Abstracts available at Global Blood Therapeutics website, www.globalbloodtx.com.
5. Ferrone FA. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016;174(4):499–500.
6. Merrett M, Stammers DK, White RD, Wootton R, Kneen G. Characterization of the binding of the anti-sickling compound, BW12C, to haemoglobin. Biochem J. 1986;239(2):387–392.
7. Beddell CR, Goodford PJ, Kneen G, White RD, Wilkinson S, Wootton R. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. Br J Pharmacol. 1984;82(2):397–407.
8. Arya R, Rolan P, W Ootton R, Posner J, Bellingham AJ. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. Br J Haematol. 1996;93(4):817–821.
9. Abdulmalik O, Safo MK, Chen Q, et al. 5-Hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Brit J Haematol. 2005;128(4):552–561.
10. Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood. 2017;129(20):2719–2726.
11. Imai K, Tientadakul P, Opartkiattikul N, et al. Detection of haemoglobin variants and inference of their functional properties using complete oxygen dissociation curve measurements. Br J Haematol. 2001;112(2):483–487.
12. Benesch R, Ranney HM, Benesch R, Smith GM. The chemistry of the Bohr effect. II. Some properties of hemoglobin H. J Biol Chem. 1961;236(11):2926–2929.
13. Bunn HF, Forget BG, Hemoglobinopathy due to abnormal oxygen binding. In: Bunn HF, Forget BG, eds. Hemoglobin: Molecular, Genetic Clinical Aspects. WB Saunders, New York, NY; 1986:610
14. Wilson DF, Erecińska M, Drown C, Silver IA. Effect of oxygen tension on cellular energetics. Am J Physiol. 1977;233(5):C135–C140.
15. Wittenberg BA, Wittenberg JB. Transport of oxygen in muscle. Annu Rev Physiol. 1989;51:857–878.
16. Erecińska M, Silver IA. Tissue oxygen tension and brain sensitivity to hypoxia. Respir Physiol. 2001;128(3):263–276.
17. 2 transport and its interaction with metabolism; a systems view of aerobic capacity. Med Sci Sports Exerc. 1992;24(1):47–53.
18. Nathan AT, Singer M. The oxygen trial: tissue oxygenation. Br Med Bull. 1999;55(1):96–108.
19. 2 transport. J Clin Invest. 1995;96(4):1916–1926.
20. Schenkman KA, Marble DR, Burns DH, Feigl EO. Myoglobin oxygen dissociation by multiwavelength spectroscopy. J Appl Physiol. 1997;82(1):86–92.
21. Hebbel RP, Eaton JW, Kronenberg RS, Zanjani ED, Moore LG, Berger EM. Adaptation to altitude in subjects with high hemoglobin oxygen affinity. J Clin Invest. 1978;62(3):593–600.
22. Rotter MA, Aprelev A, Adachi K, Ferrone FA. Molecular crowding limits the role of fetal hemoglobin in therapy for sickle cell disease. J Mol Biol. 2005;347(5):1015–1023.
23. Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the “hyperhemolysis paradigm” for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol. 2011;86(2):123–154.
24. Rowley CA, Ikeda AK, Seidel M, et al. Microvascular oxygen consumption during sickle cell pain crisis. Blood. 2014;123(20):3101–3104.
25. Pries ARl, Fritzsche A, Ley K, Gaehtgens P. Redistribution of red blood cell flow in microcirculatory networks by hemodilution. Circ Res. 1992;70(6):1113–1121.
26. Belhassen Ll, Pelle G, Sediame S, et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood. 2001;97(6):1584–1589.
27. Nath KAl, Katusic ZS, Gladwin MT. The perfusion paradox and vascular instability in sickle cell disease. Microcirculation. 2004;11(2):179–193. Mar
28. Jordan LC, DeBaun MR. Cerebral hemodynamic assessment and neuroimaging across the lifespan in sickle cell disease. J Cereb Blood Flow Metab. 2017. https://doi.org/10.1177/0271678X17701763.